ITM Isotope Technologies Munich (ITM) has signed an agreement with TerThera BV for supplies of Terbium-161 (Tb-161) to support the development of its Tb-161-based pipeline candidates.
Currently, ITM is investigating the use of Tb-161-based radiopharmaceuticals for treating various types of cancers. Like Lutetium-177, Tb-161 emits medium-range beta particles and has a similar half-life. However, Tb-161 also emits low-energy Auger and internal conversion electrons, delivering highly localized radiation that can effectively target isolated cancer cells and micro-metastases with minimal off-target effects, ITM noted.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
